截至7月31日，华熙生物股东户数3.25万，较上期增加1.78%；人均流通股14799股，较上期减少1.75%。 2025年1月-6月，华熙生物实现营业收入22.61亿元，同比减少19.57%；归母净利润2.21亿元，同比减少 35.38%。 9月23日，华熙生物盘中下跌2.00%，截至10:09，报54.34元/股，成交5716.50万元，换手率0.22%，总市 值261.74亿元。 资金流向方面，主力资金净流出544.07万元，特大单买入0.00元，占比0.00%，卖出259.92万元，占比 4.55%；大单买入1049.06万元，占比18.35%，卖出1333.20万元，占比23.32%。 华熙生物今年以来股价涨6.70%，近5个交易日跌7.00%，近20日跌6.60%，近60日涨5.29%。 资料显示，华熙生物科技股份有限公司位于山东省济南市高新技术开发区天辰大街678号，成立日期 2000年1月3日，上市日期2019年11月6日，公司主营业务涉及微生物发酵和交联两大技术平台,开发有助 于人类生命健康的生物活性材料,建立了从原料到医疗终端产品、功能性护肤品及功能性食品的全产业 链业务体系,服务于全球的 ...

Company Overview - Huaxi Biological Technology Co., Ltd. is located in Jinan, Shandong Province, established on January 3, 2000, and listed on November 6, 2019. The company specializes in microbial fermentation and cross-linking technology platforms, developing bioactive materials that benefit human health. It has established a full industry chain from raw materials to medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing companies, medical institutions, and end-users [2]. Financial Performance - As of July 31, the number of Huaxi Biological shareholders reached 32,500, an increase of 1.78% from the previous period. The average circulating shares per person decreased by 1.75% to 14,799 shares [2]. - For the first half of 2025, Huaxi Biological reported operating revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%. The net profit attributable to the parent company was 221 million yuan, down 35.38% year-on-year [2]. Stock Performance - Huaxi Biological's stock price has increased by 14.59% year-to-date, with a 1.81% rise over the last five trading days, a 13.65% increase over the last 20 days, and a 6.69% increase over the last 60 days [2]. - On September 1, the stock price rose by 2.03%, reaching 58.36 yuan per share, with a trading volume of 246 million yuan and a turnover rate of 0.89%. The total market capitalization stood at 28.111 billion yuan [1]. Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders included various ETFs, with notable changes in holdings. For instance, Huaxia SSE Sci-Tech Innovation Board 50 ETF held 10.6429 million shares, down 244,800 shares from the previous period. Meanwhile, the E Fund SSE Sci-Tech Innovation Board 50 ETF increased its holdings by 227,800 shares to 7.9777 million shares [3].